Lab tests: Eli Lilly, Regeneron antibody therapies lose out against Omicron
German researchers have found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron variant of... | December 14, 2021
Source: marketscreener.com